Clinical trial NCT07026370: China Pulmonary Health Study
Official title: The China Pulmonary Health Study: Baseline Survey, and Follow-up Investigation
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Chronic Respiratory Diseases
Cardiovascular and Cerebrovascular Diseases
Malignant Tumors
Endocrine and Metabolic Diseases
Multimorbidities
Keywords: Multimorbidities
Epidemiological survey
Cohort
Population medicine
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2025-06-18
Enrollment: 50991
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total number of 50,991 adults aged 20 years or older from 10 representative provinces and municipalities of China participated in the CPHS baseline survey between 2011 and 2014. In the follow-up investigation, ideally all the baseline participants should be contacted.

Brief summary: The China Pulmonary Health Study (CPHS) was a large-scale epidemiological survey designed to investigate the pulmonary health of Chinese adults aged 20 years or older leveraging a multistage stratified sampling scheme between 2011 and 2014 in mainland China. Briefly, a total number of 57,779 local residents were recruited from 10 representative provinces and municipalities and were invited to participate in the study. A final number of 50,991 adults who met the major inclusion criteria could be considered in further analyses.

In order to investigate the changes of pulmonary health and disease status (e.g. occurrence and development of chronic respiratory diseases and other important relevant multimorbidities, lung function indices, etc.) and corresponding impact factors in the CPHS study population, we plan to initiate the first round of follow-up investigation in 2025 and 2026, i.e. 10-15 years after the baseline survey.


Eligibility criteria: Inclusion Criteria:

* (1) the individuals who participated in the CPHS baseline survey;
* (2) their ID number and phone number are available;
* (3) sign the informed consent.

Exclusion Criteria:

* (1) incapable of taking pre- and post-bronchodilator spirometry tests;
* (2) request to withdraw the informed consent;
* (3) terminate due to medical or ethical considerations judged by the investigators and/or ethics committee.

Primary outcomes:
measure: Occurrence of multimorbidities
timeFrame: Since baseline survey till year 2025 and 2026 (the first round of follow-up investigation of CPHS)
Secondary outcomes:
measure: Changes of lung function, forced expiratory volume in one second (FEV1)
timeFrame: Since baseline survey till year 2025 and 2026 (the first round of follow-up investigation of CPHS)
measure: Changes of lung function, forced vital capacity (FVC)
timeFrame: Since baseline survey till year 2025 and 2026 (the first round of follow-up investigation of CPHS)
measure: Changes of lung function, FEV1/FVC
timeFrame: Since baseline survey till year 2025 and 2026 (the first round of follow-up investigation of CPHS)
measure: Changes of lung function, the percentage of measured FEV1 value to the predicted value (FEV1%pred)
timeFrame: Since baseline survey till year 2025 and 2026 (the first round of follow-up investigation of CPHS)
Other outcomes:
Locations:
city: Beijing
country: China
facility: China-Japan Friendship Hospital
state: Beijing
Study officials:
References:
citation: Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.
citation: Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Chen Y, Sun T, Shan G, Lin Y, Xu G, Wu S, Wang C, Wang R, Shi Z, Xu Y, Ye X, Song Y, Wang Q, Zhou Y, Li W, Ding L, Wan C, Yao W, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Wang Z, Chen Z, Bu X, Zhang H, Zhang X, An L, Zhang S, Zhu J, Cao Z, Zhan Q, Yang Y, Liang L, Tong X, Dai H, Cao B, Wu T, Chung KF, He J, Wang C; China Pulmonary Health (CPH) Study Group. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019 Aug 3;394(10196):407-418. doi: 10.1016/S0140-6736(19)31147-X. Epub 2019 Jun 20.
citation: Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Yao W, Sun T, Shan G, Yang T, Lin Y, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Hou G, Zhou Y, Li W, Ding L, Wang H, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Liang L, Liu Z, Zhang X, Cheng A, Cao B, Dai H, Chung KF, He J, Wang C; China Pulmonary Health Study Group. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020 Nov;8(11):1081-1093. doi: 10.1016/S2213-2600(20)30155-7. Epub 2020 Jun 26.